Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 30, Issue 8, Pages 712-714Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e31820fc8e1
Keywords
daptomycin; pediatric; pharmacokinetics
Categories
Funding
- Targanta Therapeutics
- Roche
- AstraZeneca
- Bristol-Myers Squibb
- Johnson and Johnson
- Pfizer
Ask authors/readers for more resources
A pharmacokinetic analysis was performed for single intravenous doses of daptomycin 8 or 10 mg/kg in subjects aged 2 to 6 years. Proportional increases in maximum plasma concentration (68.4 mu g/mL, 79.2 mu g/mL) and area under the curve (429.1 mu g.h/mL, 549.7 mu g.h/mL) were observed for each dose cohort, respectively. Half-life, clearance, and distribution volume were similar between groups. Both doses were well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available